This Month in JNM

Enhancing PET technologies: Levin offers an overview of innovations in photon detection that may enable identification of more limited numbers of cells in tissues or characterization of lower abundance of molecular targets within cells.Page 167

¹³N-ammonia PET/CT and MBF: Slomka and colleagues compare results obtained from 3 software tools for quantitation of PET myocardial blood flow and reserve.Page 171

Clinical value of ¹⁸F-FES PET: Kruchten and colleagues assess the added information provided by PET with this estrogen receptor–specific tracer in breast cancer patients presenting with inconclusive results after standard work-ups.Page 182

PET/CT in retinoblastoma: Radhakrishnan and colleagues investigate the role of ¹⁸F-FDG PET/CT in staging, neoadjuvant chemotherapy response evaluation, and final outcome assessment in stage III retinoblastoma.Page 191

¹¹C-4DST PET/CT for NSCLC: Minamimoto and colleagues look at the potential of this new tracer, a proposed in vivo cell proliferation marker, for PET/CT imaging in patients with non–small cell lung cancer.Page 199

¹⁸F-FET PET metaanalysis: Dunet and colleagues provide a systematic review and metaanalysis of published reports on the diagnostic performance of this imaging tracer in patients with suspected primary brain tumors.Page 207

¹⁵³Sm-EDTMP dosimetry: Senthamizhchelvan and colleagues analyze the influence of administered activity, osteosarcoma tumor density and mass, and tumor shape on the absorbed dose of this promising radiopharmaceutical therapy that also facilitates scintigraphic imaging.Page 215

SUV change and lung cancer outcomes: Guerra and colleagues explore associations between maximum standardized uptake values on ¹⁸F-FDG PET before and after radiation therapy and survival outcomes for patients with locally advanced non–small cell lung cancer.Page 225

TSPO expression in epilepsy: Hirvonen and colleagues use ¹¹C-PBR28 PET and MRI to determine whether expression of translocator protein, a marker of inflammation, is increased ipsilateral to seizure foci in patients with temporal lobe epilepsy.Page 234

¹⁸F-FDG in cardiac sarcoidosis: Youssef and colleagues present a systematic review and metaanalysis of studies that evaluate the accuracy of ¹⁸F-FDG PET for diagnosis of cardiac sarcoidosis, using Japanese guidelines and also including data from a Canadian registry.Page 241

PET in triple-negative breast cancer: Groheux and colleagues investigate whether early changes in ¹⁸F-FDG tumor uptake during neoadjuvant chemotherapy can predict outcomes in patients with this aggressive breast cancer subtype.Page 249

SPECT/CT dosimetry in liver cancer: Garin and colleagues use ^99mTc-MAA SPECT/CT to calculate tumor and nontumor dosimetry in patients with hepatocellular carcinoma undergoing treatment with ⁹⁰Y-loaded glass microspheres.Page 255

PET in paragangliomas: David Taïeb and colleagues provide an educational overview of PET imaging of these rare endocrine tumors with currently available and in-development tracers and discuss the related roles of imaging phenotypes and molecular genetics.Page 264

Nucleoside PET for personalized therapy: Lee and colleagues explore a novel PET assay using ¹⁸F-FAC and a related probe to profile tumor lesions for specific enzymatic activities, with implications for tailoring nucleoside analog chemotherapy to individual needs.Page 275

PET and response to ADI therapy: Stelter and colleagues analyze data from preclinical models of melanoma to determine whether ¹⁸F-FDG assessments of response to therapy with arginine deiminase may be used to predict benefit or outcomes.Page 281

PET and TSPO expression in glioma: Tang and colleagues evaluate a high-affinity pyrazolopyrimidinyl-based translocator protein imaging ligand as a translational probe for quantification of TSPO levels in glioma.Page 287

Radioligand for 5-HT6 receptors: Parker and colleagues describe preclinical studies with a promising ¹¹C-labeled tracer that could enable in vivo imaging of brain 5-HT6 receptors, assessment of their involvement in disease pathology, and development of novel therapeutics.Page 295

Monitoring EpoR in cancer: Doleschel and colleagues detail the development of a novel erythropoietin receptor probe for fluorescence-mediated tomography investigation of these receptors in human lung cancer xenografts.Page 304

Cerenkov luminescence and therapy monitoring: Xu and colleagues explore the use of Cerenkov luminescence imaging to monitor drug efficacy in tumor xenografts and compare their results with those from PET.Page 312

RGD uptake and LV remodeling: Sherif and colleagues investigate whether myocardial ¹⁸F-galacto-RGD uptake on PET early after myocardial infarction in rats is associated with long-term left ventricular remodeling.Page 318

Automatic ictal SPECT injection: Setoain and colleagues assess the performance and clinical usefulness of an automated injector system for ictal SPECT that calculates the volume of tracer to be injected over time.Page 324

Human dosimetry of ¹¹C-DPA-713: Endres and colleagues use whole-body PET/CT to characterize the radiation dosimetry of ¹¹C-DPA-713, a specific PET ligand for assessment of translocator protein.Page 330

PET coverage workshop: Hillman and other participants review the proceedings of a Medical Imaging and Technology Alliance–sponsored workshop to consider new pathways for Medicare coverage of PET radiopharmaceuticals and imaging procedures currently subject to a national noncoverage decision.Page 336

ON THE COVER

¹⁸F-FES, an estrogen receptor–specific PET tracer with various potential interesting applications, has been found to be a valuable additional diagnostic tool when standard work-up is inconclusive. ¹⁸F-FES uptake seemed to be predominant in bone marrow of the breast cancer patient shown above, in whom laboratory signs of bone marrow infiltration were present.See page 188.

• © 2012 by the Society of Nuclear Medicine, Inc.